Perfluoroheptanoic acid (PFHpA)

If you drink well water, live near an industrial site, or work around firefighting foam, you may be carrying man-made chemicals that never fully break down. This test looks for one of them in your urine, giving you a window into what your body is currently taking in and clearing.

A number on a lab report turns an invisible exposure into something you can actually track. The catch is that urine tells you about recent exposure, not the full amount stored in your body.

What This Chemical Actually Is

PFHpA (perfluoroheptanoic acid) belongs to a family of thousands of synthetic chemicals called PFAS (per- and polyfluoroalkyl substances), widely nicknamed forever chemicals because their carbon-and-fluorine bonds resist breaking down. Your body cannot make it and does not need it. Every molecule in you came from outside, through contaminated water, dust, food, or consumer and industrial products.

PFHpA is classed as a short-chain PFAS because its fluorinated backbone (seven carbons) is one carbon shorter than legacy compounds like PFOA (eight carbons) and PFOS. These short-chain versions were introduced as replacements for the legacy compounds, and they now turn up widely in homes and people. A shorter chain also means your kidneys clear it faster, which shapes what a urine test can and cannot tell you, though the difference from PFOA is smaller than the label might suggest.

What a Urine Test Captures, and What It Misses

Your kidneys are the main exit route for short-chain PFAS, so urine reflects what you are excreting now rather than the total amount banked in your blood and tissues. For chemicals that do not linger, urine can be a useful sample for spotting recent exposure.

There is an important limit. In the U.S. general population, urinary PFAS are often undetectable: in one national survey, 67.5% of people had no detectable level of any of 17 PFAS in urine, and the authors concluded their data do not support urine biomonitoring of short-chain PFAS in the general population. Detection is far higher in exposed groups; among 189 children in Shanghai, PFHpA appeared in 99.5% of urine samples at a middle value of 46.5 ng/L (nanograms per liter, a very small concentration unit). A not-detected urine result does not prove you have no exposure, especially since PFHpA is usually found more often in blood than in urine.

Where Exposure Comes From

PFHpA gets into people through everyday routes. In paired home-and-body sampling, levels in tap water and household dust tracked with levels in blood, marking these as important pathways in.

• Contaminated drinking water: private wells and systems near industry or firefighting foam use are the highest-risk sources.
• Indoor dust: settled dust in homes and workplaces can be ingested and correlates with body levels.
• Diet: red meat, fish and seafood, eggs, and sugary drinks have been tied to higher urinary levels in children.
• Consumer and industrial products: replacement fluorinated chemistries in packaging, coatings, and foams are broad sources.

Thyroid Cancer

One human link between urinary PFHpA and a hard outcome comes from thyroid research. In a case-control study of 290 adults in northeast China, people with papillary thyroid cancer (the most common thyroid cancer) had significantly higher urinary PFHpA than those without it, and higher exposure tracked with higher cancer risk in a non-straight-line pattern. This is a single observational study and cannot prove PFHpA causes the cancer. The broader PFAS-thyroid cancer literature is mixed, with some cohorts finding no clear link and others pointing in different directions, so read this as one signal rather than a settled finding. It is notable mainly because it measured the chemical in urine, exactly as this test does.

Uric Acid and Gout

Higher PFHpA exposure has been tied to a greater chance of developing high uric acid, the driver behind gout. In a 10-year study of 654 Chinese women, those in the highest exposure group were about 1.9 times as likely to develop high uric acid as those with low exposure (odds ratio 1.86). This study measured the chemical in blood, not urine, so read it as a signal about PFHpA exposure in general rather than proof about your urine number.

Blood Vessel Function

PFHpA has been linked to early blood vessel dysfunction, a precursor to heart disease. In 94 adults with no known heart disease, each step up in blood PFHpA was tied to about 15% worse performance on a test of how well arteries widen (the brachial artery reactivity test). People in the highest third of exposure had roughly 41% worse artery function than the lowest third, and PFHpA accounted for most of the effect seen from a mixture of PFAS. This finding used blood, not urine.

Kidney Function

Kidney findings are real but tangled. In a longitudinal study of nearly 1,000 adults, higher blood PFHpA went with lower kidney filtration (measured as eGFR, a filtration score), and in teenagers living near a Chinese chemical plant, PFHpA was associated with higher odds of chronic kidney disease. Yet some analyses point the opposite way, with higher PFHpA appearing alongside better filtration.

This apparent contradiction has a likely explanation, and it matters for how you read any single result. PFHpA is not a simple higher-equals-worse marker for the kidney. Because the kidney is also the organ that clears PFHpA, failing kidneys can change how much of the chemical is retained or excreted, which can push blood and urine levels in confusing directions. The relationship can run both ways, so a PFHpA level is best interpreted alongside actual kidney tests rather than on its own.

Fatty Liver Disease

Higher PFHpA has been linked to more severe fatty liver disease. In a study using liver biopsies, PFHpA was higher in people with more advanced fat buildup and scarring, and in a separate analysis of 1,751 adults, a detectable PFHpA level was tied to 54% higher odds of fatty liver disease than an undetectable level. Both studies measured PFHpA in blood.

Why One Reading Is Not Enough

PFHpA is not a fixed trait. Its levels swing with recent exposure, and it clears relatively fast: after a contaminated-water exposure ended, blood PFHpA fell with a half-life of about 62 days, far quicker than legacy chemicals that persist for years. A single urine reading is a snapshot of a moving target.

That short half-life is exactly why tracking beats a one-off test. A baseline tells you whether you are being exposed now; a repeat months later shows whether a change, like switching water sources or filtering your water, is working. A reasonable approach is a baseline, a retest in 3 to 6 months if you change your environment, and at least annual checks if you have ongoing exposure concerns. These intervals are not drawn from any clinical guideline; they simply reflect how quickly PFHpA clears. Because urinary PFHpA reflects the same recent exposure the studies describe, retesting to confirm a source has dropped is a fair use of this specific measurement.

What to Do With an Unexpected Result

A high or newly detectable urinary PFHpA is a prompt to investigate your environment and your other labs, not a diagnosis on its own.

• Hunt the source: test your drinking water, especially a private well, and consider whether firefighting foam, industrial work, or a contaminated area is nearby.
• Pair it with blood: because urine misses much of the stored burden, a serum PFAS panel gives a fuller picture, and combining the two is the strongest way to interpret exposure.
• Check the organs implicated: review uric acid, kidney filtration (eGFR and cystatin C), thyroid tests, cholesterol, and liver markers to see whether any downstream signal is present.
• Bring in help: a clinician familiar with environmental exposures or a toxicologist can put the numbers in context and guide next steps.

When a Single Reading Can Fool You

Because urinary PFHpA is variable, several things can distort one measurement.

• Urine dilution: a watered-down or concentrated sample shifts the raw number, so labs adjust using creatinine, and unadjusted spot values can mislead.
• Timing of exposure: with a short half-life, a sample taken long after an exposure can read low even if your body burden was recently high.
• Kidney function: how fast you clear PFHpA depends on kidney health, age, and body size, so the same exposure can produce different urine levels in different people.
• Detection limits: PFHpA often sits near the lowest level an assay can measure, so a not-detected result can reflect a sensitivity ceiling rather than true absence.